Spinal Enfeksiyonlarda Konservatif Tedavinin Komplikasyonları

Ascione T, Balato G, Di Donato SL, et al. Clinical and microbiological outcomes in haematogenous spondylodiscitis treated conservatively. European spine journal . 2017 Oct;26(Suppl 4):489-495. doi: 10.1007/s00586-017-5036-4.

Bettini N, Girardo M, Dema E, et al. Evaluation of conservative treatment of non specific spondylodiscitis. European spine journal. 2009 Jun;18 Suppl 1:143-50. doi: 10.1007/s00586-009-0979-8.

Valancius K, Hansen ES, Høy K, et al. Failure modes in conservative and surgical management of infectious spondylodiscitis. European spine journal. 2013 Aug;22(8):1837-44. doi: 10.1007/s00586-012-2614-3.

Cortet B, Richard R, Deprez X et al. Aspergillus spondylodiscitis: successful conservative treatment in 9 cases. The Journal of rheumatology 1994; 21:1287–1291.

Rutges JP, Kempen DH, van Dijk M et al. Outcome of conservative and surgical treatment of pyogenic spondylodiscitis: a systematic literature review. European spine journal. 2016; 25:983–999 27.

Homagk L, Homagk N, Klauss JR et al. Spondylodiscitis severity code: scoring system for the classification and treatment of non-specific spondylodiscitis. . European spine journal. 2016;25:1012–1020.

Lee SH, Kim J, Kim TH. Treatment Guideline for Patients with Native Culture-negative Pyogenic Vertebral Osteomyelitis. Clinical orthopaedics and related research. 2022 Jan 1;480(1):124-136. doi: 10.1097/CORR.0000000000001866.

Bernard L, Dinh A, Ghout I, et al. Duration of Treatment for Spondylodiscitis (DTS) study group. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet. 2015 Mar 7;385(9971):875-82. doi: 10.1016/S0140-6736(14)61233-2.

Gregori F, Grasso G, et al. Treatment algorithm for spontaneous spinal infections: A review of the literature. Journal of craniovertebral junction & spine. 2019 Jan-Mar;10(1):3-9. doi: 10.4103/jcvjs.JCVJS_115_18.

Issa K, Diebo BG, Faloon M, et al. The Epidemiology of Vertebral Osteomyelitis in the United States From 1998 to 2013. Clinical spine surgery. 2018 Mar;31(2):E102-E108. doi: 10.1097/BSD.0000000000000597.

11 Glicksman M, Jow S, Malmut L. Celecoxib for Management of Refractory Back Pain Secondary to Vertebral Osteomyelitis: A Case Report. Journal of medical cases. 2021 Jul;12(7):291-294. doi: 10.14740/jmc3699.

Petkova AS, Zhelyazkov CB, Kitov BD. Spontaneous Spondylodiscitis -Epidemiology, Clinical Features, Diagnosis and Treatment. Folia medica. 2017 Sep 1;59(3):254-260. doi: 10.1515/folmed-2017-0024.

Migliorini F, Maffulli N, Eschweiler J, et al. The pharmacological management of chronic lower back pain. Expert opinion on pharmacotherapy. 2021 Jan;22(1):109-119. doi: 10.1080/14656566.2020.1817384.

Cashin AG, Wand BM, O'Connell NE, et al. Pharmacological treatments for low back pain in adults: an overview of Cochrane Reviews. The Cochrane database of systematic reviews. 2023 Apr 4;4(4):CD013815. doi: 10.1002/14651858.CD013815.pub2.

Yılmaz G, Aydın K, Antinikrobiyallerin karaciğer dışı istenmeyen yan etkileri. Eds: Leblebicioğlu H, Usluer G, Ulusoy S. Güncel Bilgiler Işığında Antibiyotikler. Sayfa:183-198

Weiss WE, Adkinson NF, Beta-lactam Allergy. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases 7th ed. Chapter 24, P:347-354

Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet. 2019 Jan 12;393(10167):183-198. doi: 10.1016/S0140-6736(18)32218-9.

Dilley M, Geng B. Immediate and Delayed Hypersensitivity Reactions to Antibiotics: Aminoglycosides, Clindamycin, Linezolid, and Metronidazole. Clinical Review of Allergy Immunology. 2022 Jun;62(3):463-475. doi: 10.1007/s12016-021-08878-x.

Sousa-Pinto B, Fonseca JA, Gomes ER. Frequency of self-reported drug allergy: A systematic review and meta-analysis with meta-regression. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2017 Oct;119(4):362-373.e2. doi: 10.1016/j.anai.2017.07.009.

Prasad R, Singh A, Gupta N. Adverse drug reactions in tuberculosis and management. The Indian journal of tuberculosis. 2019 Oct;66(4):520-532. doi: 10.1016/j.ijtb.2019.11.005.

Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut and liver. 2014 Jan;8(1):1-6. doi: 10.5009/gnl.2014.8.1.1.

Tamma PD, Avdic E, Li DX, et al. Association of Adverse Events With Antibiotic Use in Hospitalized Patients. Journal of the American Medical Association internal medicine. 2017 Sep 1;177(9):1308-1315. doi: 10.1001/jamainternmed.2017.1938.

Navarro VJ, Senior JR. Drug-related hepatotoxicity, The New England journal of medicine. 2006;354(7):731-739. http://dx.doi.org/10.1056

Öncü S. Antibiyotiklerin istenmeyen etkilerinin izlemi-yönetimi. ANKEM Dergisi 2013;27(Ek 2):82-84

Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury, World journal of gastroenterology.2008;14(44):6774- 6785

Vandendries ER, Drews RE. Drug-associated disease: hematologic dysfunction. Critical care clinics. 2006 Apr;22(2):347-355, viii. doi: 10.1016/j.ccc.2006.02.002

Taber SS, Mueller BA. Drug-associated renal dysfunction. Critical care clinics. 2006 Apr;22(2):357-74, viii. doi: 10.1016/j.ccc.2006.02.003.

Joyce EL, Kane-Gill SL, Fuhrman DY, et al. Drug-associated acute kidney injury: who's at risk? Pediatric nephrology: journal of the International Pediatric Nephrology Association.2017 Jan;32(1):59-69. doi: 10.1007/s00467-016-3446-x.

Iannini PB. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert opinion on drug safety.2002 Jul;1(2):121-8. doi: 10.1517/14740338.1.2.121.

Karadimas EJ, Bunger C, Lindblad BE, et al. Spondylodiscitis. A retrospective study of 163 patients. Acta orthopaedica. 2008;79:650–659. doi: 10.1080/17453670810016678.